Although topotecan has a generalized effect on long genes associated with autism (King et al., 2013) that may halt its widespread use as a therapeutic agent to treat AS, this seminal study showed that pharmacological perturbation of UBE3A-ATS transcription is a feasible approach to reinstate UBE3A expression in AS individuals. Here, UBE3A is linked to autism.